vs
Side-by-side financial comparison of PubMatic, Inc. (PUBM) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
PubMatic, Inc. is the larger business by last-quarter revenue ($80.0M vs $60.1M, roughly 1.3× RHYTHM PHARMACEUTICALS, INC.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -6.4%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 9.5%).
PubMatic, Inc. develops and implements online advertising software and strategies for the digital publishing and advertising industry. PubMatic's sell-side, real-time programmatic ad transaction advertising software puts publishers of websites, videos, and mobile apps into contact with ad buyers by using automated systems, while allowing users to opt-out of having their personal information collected on internet searches. PubMatic has a number of offices in countries around the world.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
PUBM vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $80.0M | $60.1M |
| Net Profit | — | $-55.6M |
| Gross Margin | 68.2% | 88.1% |
| Operating Margin | 10.6% | -87.1% |
| Net Margin | — | -92.6% |
| Revenue YoY | -6.4% | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.14 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $80.0M | $57.3M | ||
| Q3 25 | $68.0M | $51.3M | ||
| Q2 25 | $71.1M | $48.5M | ||
| Q1 25 | $63.8M | $32.7M | ||
| Q4 24 | $85.5M | $41.8M | ||
| Q3 24 | $71.8M | $33.3M | ||
| Q2 24 | $67.3M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-6.5M | $-52.9M | ||
| Q2 25 | $-5.2M | $-46.6M | ||
| Q1 25 | $-9.5M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-912.0K | $-43.6M | ||
| Q2 24 | $2.0M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | 68.2% | 91.6% | ||
| Q3 25 | 62.6% | 89.3% | ||
| Q2 25 | 62.6% | 88.6% | ||
| Q1 25 | 59.9% | 88.8% | ||
| Q4 24 | 70.8% | 90.9% | ||
| Q3 24 | 64.5% | 88.5% | ||
| Q2 24 | 62.6% | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 10.6% | -82.2% | ||
| Q3 25 | -12.4% | -102.6% | ||
| Q2 25 | -7.7% | -93.4% | ||
| Q1 25 | -18.6% | -143.7% | ||
| Q4 24 | 17.3% | -98.6% | ||
| Q3 24 | -1.9% | -132.0% | ||
| Q2 24 | -5.9% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | -9.5% | -103.1% | ||
| Q2 25 | -7.3% | -96.1% | ||
| Q1 25 | -14.9% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -1.3% | -131.2% | ||
| Q2 24 | 2.9% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $0.14 | $-0.73 | ||
| Q3 25 | $-0.14 | $-0.82 | ||
| Q2 25 | $-0.11 | $-0.75 | ||
| Q1 25 | $-0.20 | $-0.81 | ||
| Q4 24 | $0.26 | $-0.71 | ||
| Q3 24 | $-0.02 | $-0.73 | ||
| Q2 24 | $0.04 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $145.5M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.6M | $122.9M |
| Total Assets | $680.2M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $145.5M | $388.9M | ||
| Q3 25 | $136.5M | $416.1M | ||
| Q2 25 | $90.5M | $291.0M | ||
| Q1 25 | $101.8M | $314.5M | ||
| Q4 24 | $100.5M | $320.6M | ||
| Q3 24 | $78.9M | $298.4M | ||
| Q2 24 | $73.5M | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $262.6M | $139.1M | ||
| Q3 25 | $245.1M | $148.8M | ||
| Q2 25 | $243.3M | $-11.9M | ||
| Q1 25 | $275.6M | $18.9M | ||
| Q4 24 | $277.3M | $21.7M | ||
| Q3 24 | $263.2M | $11.2M | ||
| Q2 24 | $282.7M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $680.2M | $480.2M | ||
| Q3 25 | $676.2M | $506.9M | ||
| Q2 25 | $675.2M | $372.7M | ||
| Q1 25 | $668.6M | $386.7M | ||
| Q4 24 | $739.5M | $392.3M | ||
| Q3 24 | $689.1M | $363.6M | ||
| Q2 24 | $673.1M | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | — |
| Free Cash FlowOCF − Capex | $11.3M | — |
| FCF MarginFCF / Revenue | 14.1% | — |
| Capex IntensityCapex / Revenue | 8.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $66.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $18.2M | $-25.4M | ||
| Q3 25 | $32.4M | $-26.6M | ||
| Q2 25 | $14.9M | $-23.3M | ||
| Q1 25 | $15.6M | $-40.4M | ||
| Q4 24 | $18.0M | $-18.8M | ||
| Q3 24 | $19.1M | $-25.2M | ||
| Q2 24 | $11.9M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $11.3M | — | ||
| Q3 25 | $27.7M | — | ||
| Q2 25 | $13.6M | — | ||
| Q1 25 | $14.2M | — | ||
| Q4 24 | $13.7M | — | ||
| Q3 24 | $7.4M | — | ||
| Q2 24 | $11.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | — | ||
| Q3 25 | 40.8% | — | ||
| Q2 25 | 19.1% | — | ||
| Q1 25 | 22.2% | — | ||
| Q4 24 | 16.1% | — | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 16.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | — | ||
| Q3 25 | 6.9% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 16.3% | — | ||
| Q2 24 | 1.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
